Press

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Jun 17 • 3 min read

Mydecine Innovations Group (NEO: MYCO | OTC: MYCOF | FSE: 0NFA), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product. The…

Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives

Jun 16 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it is bolstering its IP with the filing of provisional patent applications to protect data it obtained during its psilocybin preclinical studies and provide protection…

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Mental Health Disorders

Jun 15 • 4 min read

Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders, is pleased to announce today the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario. The Kitchen-waterloo location is the fifth Braxia…

Filament Health Cultivates 70th Variety of Psilocybin-containing Mushrooms At Vancouver Facility

Jun 14 • 1 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) cultivated its 70th variety of psilocybin-containing mushrooms at its 3,500 square foot GMPcompliant facility in Metro Vancouver. Filament also announced the successful development of standardized, pharmaceutical grade ayahuasca extract, designed for oral administration by capsule or tablet. The drug product was manufactured using Filament’s proprietary processing…

Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives

Jun 13 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that the United States Patent and Trademark Office (‘USPTO’) has issued a Notice of Allowance for Mindset’s patent application…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427